Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexMale
Age18-89
SponsorNorthwestern University

About this trial

Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration. With increasing surgical efficiency from improvements in laser and morcellator technology, the role of intra-operative furosemide is unknown. This study is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP) with and without IV furosemide. .

Eligibility criteria

Qualifiers

Males 18 -89 undergoing HoLEP

Willing to sign the Informed Consent Form

Able to read, understand, and complete patient questionnaires.

Disqualifiers

Allergy or hypersensitivity to furosemide or other loop diuretic

Anuric patients or patients with liver failure

Patients having a concurrent ureteroscopy +/- laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at the time of their HoLEP

Anticipated need for perineal urethrostomy at the time of HoLEP

Trial design

Treatments tested in this trial

  • Furosemide

Treatment groups

138 Participants
are divided into 2 treatment groups

Sponsors and collaborators